Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population
CALLISTO
Investigation Into the CorrelAtion of pLasma Hs-CRP Concentrations and cardiovascuLar rISk in Korean populaTiOn
1 other identifier
observational
1,700
1 country
10
Brief Summary
An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2009
Shorter than P25 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2009
CompletedFirst Posted
Study publicly available on registry
January 8, 2009
CompletedStudy Start
First participant enrolled
March 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2009
CompletedDecember 6, 2010
December 1, 2010
5 months
January 7, 2009
December 2, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluate hs-CRP levels according to risk categories by the NCEP ATP III.
Within the last 12 months from the date of data entry.
Secondary Outcomes (1)
Evaluate a relationship between hs-CRP and each CHD CVD risk factor including LDL-C.
Within the last 12 months from the date of data entry.
Study Arms (1)
1
patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
Eligibility Criteria
Patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
You may qualify if:
- Subjects with at least one clinic visit record within the last 12 months from the date of data entry.
- Subjects with at least one hs-CRP level measured within the last 12 months from the date of data entry.
You may not qualify if:
- Use of statins or other lipid-lowering therapies including fibrates, niacin, and bile acid sequestrants in the past 3 months prior to hsCRP measurement
- Active inflammatory diseases documented during the period of CRP measurement
- Subjects taking immunosuppressants
- Findings of chronic inflammation: arthritis, lupus, or inflammatory bowel disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (10)
Research Site
Wŏnju, Gangwon-do, South Korea
Research Site
Anyang-si, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Uijeongbu-si, Gyeonggi-do, South Korea
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Jeonju, South Korea
Research Site
Kwangju-si, South Korea
Research Site
Seoul, South Korea
Study Officials
- PRINCIPAL INVESTIGATOR
Baek Sanghong, Ph.D.
The Catholic University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
January 7, 2009
First Posted
January 8, 2009
Study Start
March 1, 2009
Primary Completion
August 1, 2009
Study Completion
August 1, 2009
Last Updated
December 6, 2010
Record last verified: 2010-12